<DOC>
	<DOCNO>NCT01117038</DOCNO>
	<brief_summary>The purpose study determine change blood pressure pulse rate , pharmacokinetics safety avanafil take either enalapril amlodipine .</brief_summary>
	<brief_title>Drug Interaction Study Avanafil Enalapril Amlodipine</brief_title>
	<detailed_description />
	<mesh_term>Erectile Dysfunction</mesh_term>
	<mesh_term>Enalapril</mesh_term>
	<mesh_term>Enalaprilat</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>1 . Voluntarily consent participate study ( informed consent form [ ICF ] must sign date prior study related assessment ) . 2 . Adult male subject 40 65 year age , inclusive . 3 . A body weight least 50 kg body mass index ( BMI ) 18 32 kg/m2 , inclusive [ BMI calculate weight kg/ ( height ) 2 ] . 4 . Subjects able communicate Investigator , understand comply requirement study participation . 5 . Medically healthy , clinically significant screen result ( e.g. , laboratory profile , medical history , ECGs , physical examination , etc . ) , opinion Investigator . 1 . A history presence significant cardiovascular ( include thromboembolic disorder ) , neurological , hematological , psychiatric , hepatic , gastrointestinal , pulmonary , endocrine , immunologic , renal disease , condition know interfere absorption , distribution , metabolism , excretion drug place subject increase risk determine Investigator . 2 . Any clinically significant laboratory abnormality judge Investigator . 3 . A predisposition priapism , subject sickle cell disease blood dyscrasia . 4 . Known history cardiovascular cerebrovascular event , history angina . 5 . History faint vasovagal hypotension . 6 . History ECG evidence highrisk arrhythmia ECG judge Investigator clinically significant . 7 . Hypertrophic obstructive clinically significant cardiomyopathy , moderate severe cardiac valvular disease . 8 . Subjects whose pulse low 50 bpm screening . 9 . Acute illness , especially infection , within 2 week dose . 10 . Supine systolic blood pressure &lt; /= 100 &gt; /= 140 mmHg ; supine diastolic blood pressure &lt; /= 50 &gt; /= 95 mmHg screening ( 2 rechecks allow ) . 11 . Subjects orthostatic hypotension ( evidence reduction 30 mmHg systolic blood pressure , reduction 20 mmHg diastolic blood pressure , evidence cerebral hypoperfusion upon stand seat position ) . 12 . Any history bipolar disorder psychosis , history psychiatric hospitalization , great one lifetime episode major depression . 13 . Hemoglobin &lt; 12.0 g/dL . 14 . Positive urine drug test , positive urine alcohol test , positive urine cotinine test screen checkin Day 1 . 15 . Positive test human immunodeficiency virus ( HIV ) , hepatitis B surface antigen ( HBsAg ) , hepatitis C antibody ( HCV ) screening . 16 . Any history presence alcoholism drug substance abuse within 18 month define Investigator . 17 . Allergy previous adverse event PDE5 inhibitor , ACE inhibitor , calcium channel blocker , constituent . 18 . Use prescription overthecounter ( OTC ) medication , include herbal product , within 14 day prior Day 1 throughout study . Up 2 g per day acetaminophen allow discretion Investigator . 19 . Use drug Appendix 1 ( drug know interfere metabolism CYP450 3A4 enzyme ) within 30 day prior Day 1 . 20 . Blood donation significant blood loss within 56 day prior Day 1 . 21 . Plasma donation within 14 day prior Day 1 . 22 . Any use tobacco nicotine product within 6 month prior Day 1 . 23 . Any subject receive investigational drug within 30 day six halflives , whichever longer , prior Day 1 . 24 . Involvement plan conduct study ( applies VIVUS designee staff , staff investigational site ) . 25 . Previously participate trial avanafil . 26 . Subjects report difficulty swallow tablet , capsule , etc .</criteria>
	<gender>Male</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>ED</keyword>
	<keyword>Erectile Dysfunction</keyword>
</DOC>